Medications That May Prevent or Delay Donation Donation centers maintain extensive lists of medications that can affect eligibility, often due to their impact on blood components, potential harm to recipients (especially during pregnancy), or risks to the donor
( Epub 2013/05/04 )
Despite these allegations, Novo Nordisk maintains that its GLP-1 medications are safe and effective, highlighting a 13-year market presence and thorough safety assessments conducted in partnership with the U.S
For patients interested in participating in research , the following resources may be helpful: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) search for Parkinson's and GLP-1 trials Parkinson's UK (www.parkinsons.org.uk) information on current research and trial opportunities When to contact your GP or specialist : If you have Parkinson's disease and diabetes, and wish to discuss whether a GLP-1 receptor agonist is appropriate for your diabetes management If you experience new or worsening symptoms whilst taking any medication If you are interested in clinical trial participationyour neurologist can advise on suitable studies Seek urgent medical attention if you experience: Severe, persistent abdominal pain (possible pancreatitis) Persistent vomiting or inability to keep fluids down (risk of dehydration) Signs of dehydration (extreme thirst, dark urine, dizziness) Allergic reaction (rash, swelling, difficulty breathing) Patients should never start, stop, or modify medications without medical supervision
